

Xbrane announces outcome of exercise of warrants of series TO1

Xbrane Biopharma AB (publ) ("Xbrane" or the "Company") today announces the outcome of the subscription period for the warrants of series TO1 (the "Warrants") issued in connection with the Company's rights issue of units during the first quarter of 2024. In total 2,706,898 Warrants were exercised for subscription of class shares, corresponding to a subscription rate of approximately one (1) percent. Xbrane will receive approximately SEK 785 thousand before issue costs.

Overview of the final outcome

The final outcome shows that 2,706,898 Warrants were exercised for subscription of shares. The utilization rate thus amounted to approximately 1.03 percent. The subscription price for a share subscribed for through the exercise of the Warrants was SEK 0.29. Xbrane thereby receives approximately SEK 785 thousand before issue costs, which are estimated to amount to approximately SEK 40 thousand.

Shares and share capital

Through the exercised Warrants, the total number of shares and votes in Xbrane will increase by 2,706,898 shares and votes, to a total of 1,532,190,295 shares and votes. The share capital of the Company increases by SEK 606,848,801,120 to SEK 343,495,707,488,169. Exercised Warrants are replaced with interim shares until registration with the Swedish Companies Registration Office takes place and the interim shares can be converted into shares. The interim shares are expected to be converted into shares approximately two banking days after registration with the Swedish Companies Registration Office.

Important information

The publication, release or distribution of this press release in certain jurisdictions may be restricted by law and persons in the jurisdictions in which this press release has been published or distributed should inform themselves about and observe any such legal restrictions. The recipient of this press release is responsible for using this press release and the information contained herein in accordance with the applicable rules in each jurisdiction. This press release does not constitute an offer, or a solicitation of any offer, to buy or subscribe for any securities in Xbrane in any jurisdiction, neither from Xbrane nor from anyone else.

This press release is not a prospectus within the meaning of Regulation (EU) 2017/1129 (the "**Prospectus Regulation**") and has not been approved by any regulatory authority in any jurisdiction.

This press release does not identify or purport to identify any risks (direct or indirect) that may be associated with an investment in the Company. Investors are encouraged to consult their own advisors in relation to an investment in the Company.

This press release does not constitute an offer or invitation to purchase or subscribe for securities in the United States. The securities referred to herein may not be sold in the United States absent registration or an applicable exemption from registration under the U.S. Securities Act of 1933, as amended (the "**Securities Act**"), and may not be offered or sold in the United States absent registration or an applicable exemption from, or in a transaction not subject to, the registration requirements of the Securities Act. There is no intention to register any securities referred to herein in the United States or to make a public offering of such securities in the United States. The information in this press release may not be announced, published, copied, reproduced or distributed, directly or indirectly, in whole or in part, in or into the United States, Australia, Belarus, Canada, Hong Kong, Japan, New Zealand, Russia, Singapore, South Africa, South Korea, Switzerland or any other jurisdiction in which such distribution would require additional prospectuses, registration or other measures in addition to those required by Swedish law, is prohibited, or otherwise contravenes applicable rules in such jurisdiction or cannot be made without the application of an exemption from such measures. Actions in violation of this instruction may constitute a violation of applicable securities legislation.

Contacts

Martin Åmark, CEO

E: martin.amark@xbrane.com

Anette Lindqvist, CFO/IR

E: anette.lindqvist@xbrane.com

About Us

Xbrane Biopharma AB develops biological drugs based on a patented platform technology that provides significantly lower production costs compared to competing systems. Xbrane has a portfolio of biosimilar candidates targeting EUR 26 billion in estimated annual peak sales of the respective reference product. The lead candidate Ximluci® is granted market authorization approval in Europe and was launched during 2023. Xbrane's head office is in Solna, just outside Stockholm. Xbrane is listed on Nasdaq Stockholm under the ticker XBRANE. For more information, visit www.xbrane.com

Attachments

[Xbrane announces outcome of exercise of warrants of series TO1](#)